Optimal Supportive Care with Selinexor Improves Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

Multiple myeloma remains incurable despite the advent of more than ten new approved therapies within the last decade.1,2 Regardless of ongoing improvement in outcomes, patients with disease refractory to multiple lines of therapy have poor outcomes with survival rates of less than 6 months in patients refractory to daratumumab.3,4 Results from the pivotal STORM study, the largest trial to date in patients with myeloma refractory to proteasome inhibitors (PI), immunomodulatory drugs (IMiD), and daratumumab (i.e., triple-class refractory), showed that therapy with selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, and low-dose dexamethasone resulted in a promising 26.2% response rate.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2021 Category: Hematology Authors: Ajai Chari, Erika Florendo, Ines Stefania Mancia, Hearn Cho, Deepu Madduri, Samir Parekh, Josh Richter, Amishi Dhadwal, Joanne Thomas, Grace Jiang, Alessandro Lagana, Sherry Bhalla, Sundar Jagannath Source Type: research